Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Abbvie Inc.

Abbott Gmbh & Co Kg

Ralf Loebbert

Ulrich Ebert

Martin Schmidt

Chung-Ming Hsieh

Jijie Gu

Reinhold Mueller

Volker Nimmrich

Enrico L Digiammarino

John E Harlan

Gerard B Fox

Zhen Wu

Feng Luo

Nicole Teusch

Achim Möller

Alfred Hahn

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.

AGER-peptides and use thereof

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid &#x3b2; and advanced glycation-end-products.

Growing community of inventors

Speyer, Germany

Ralf Loebbert